HeartBeam (NASDAQ: BEAT) announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia, a condition involving inadequate blood flow and oxygen supply to tissues. The study marks a significant step in the development of the HeartBeam patch, which could disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology offers a potential solution. Unlike existing patch-based ambulatory monitors, which have not been capable of ischemia detection, the HeartBeam patch is designed to provide clinical-grade insights over an extended period.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could significantly improve early detection and management of coronary artery disease.”
The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common. HeartBeam's pilot study aims to demonstrate the patch's ability to detect ischemia, which could lead to earlier intervention and better outcomes for patients. The company expects the study to provide critical data to support further development and regulatory submissions.
For more information, visit the company's newsroom at https://ibn.fm/BEAT. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.
